This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEB6J0AJ_M.jpg
The average one-year price target for Arcutis Biotherapeutics as of August 31, 2023, stands at $42.71, suggesting a potential increase of 693.91% from its closing price of $5.38. Price forecasts range from a low of $22.22 to a high of $59.85.
Arcutis Biotherapeutics’ projected annual revenue is expected to reach $53 million, marking a substantial growth of 375.62%. However, the company’s non-GAAP EPS is projected to be -$4.69.
Institutional sentiment towards the company appears divided. Despite a decrease in the total number of funds or institutions holding positions in Arcutis Biotherapeutics by 8.76% to 323 last quarter, the total shares owned by these institutions saw a marginal increase of 0.44% to 78,147K shares. The average portfolio weight dedicated to ARQT decreased by 21.00% to 0.11%, while the put/call ratio stands at 2.56, indicating a bearish outlook.
Several institutional shareholders adjusted their holdings in Arcutis Biotherapeutics over the previous quarter. Frazier Life Sciences Management maintained its ownership at 14.09%, with no changes reported. Rubric Capital Management increased its stake by 28.35% to now own 7.92% of the company’s shares, while SPDR S&P Biotech (NYSE:XBI) ETF raised its ownership by 34.51% to hold a 7% stake. Jennison Associates also expanded its stake by 48.43% to account for 6.96% of the company’s shares. However, Polar Capital Holdings slightly reduced its holdings by 0.25%, now owning 5.07% of the company’s shares.
Arcutis Biotherapeutics holds a promising pipeline that includes four novel drug candidates currently under development for various inflammatory skin conditions. Its leading product candidate, topical roflumilast, has the potential to set a new standard of care for numerous skin conditions including plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
